Incyte Corp
(NQ:
INCY
)
65.24
-0.88 (-1.33%)
Streaming Delayed Price
Updated: 9:57 AM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
50,220
Open
65.79
Bid (Size)
65.24 (3)
Ask (Size)
65.30 (9)
Prev. Close
66.12
Today's Range
65.22 - 65.79
52wk Range
50.27 - 70.36
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
Today 9:00 EDT
NASDAQ:INCY may be ready to breakout.
Via
Chartmill
A Look Into Incyte Inc's Price Over Earnings
October 10, 2024
Via
Benzinga
Performance
YTD
-0.32%
-0.32%
1 Month
+2.64%
+2.64%
3 Month
+1.54%
+1.54%
6 Month
+22.10%
+22.10%
1 Year
+13.20%
+13.20%
More News
Read More
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
October 10, 2024
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 08, 2024
From
Incyte
Via
Business Wire
Assessing Incyte: Insights From 11 Financial Analysts
October 01, 2024
Via
Benzinga
Incyte Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
September 03, 2024
Via
Benzinga
Analyst Expectations For Incyte's Future
August 15, 2024
Via
Benzinga
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
Via
Benzinga
Exposures
Product Safety
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
September 18, 2024
Via
Talk Markets
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
September 16, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2024
From
Incyte
Via
Business Wire
Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
August 21, 2024
From
Incyte
Via
Business Wire
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
August 16, 2024
Via
Benzinga
Exposures
Product Safety
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
August 15, 2024
From
Incyte
Via
Business Wire
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)
August 14, 2024
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
August 13, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2024
From
Incyte
Via
Business Wire
After Reporting Five Patient Deaths, Data Committee Recommends MacroGenics Halt Prostate Cancer Trial
July 31, 2024
Via
Benzinga
Topics
Death
Exposures
Death
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.